Endpoints reports the FDA rejected ITM's neuroendocrine-tumor radiopharmaceutical over manufacturing

Endpoints News reported on 10 August 2026 that the FDA rejected ITM Isotope Technologies Munich's radiopharmaceutical for neuroendocrine tumors over manufacturing issues, and that ITM said the agency cited manufacturing concerns ^[1]. Headline-only trade reports Prognyx could not resolve to publisher pages — and which are therefore named here but not cited as links — designate the action a Complete Response Letter (AuntMinnie, 10 August 2026), identify the asset as ITM-11, that is ¹⁷⁷Lu-edotreotide (The Pharma Letter, 11 August 2026), and put the filing in gastroenteropancreatic neuroendocrine tumors (Oncology News Central, 11 August 2026). The same class of headline reports a phase 3 success in January 2025 (Labiotech.eu, 28 January 2025) and additional data at ESMO 2025 described as strengthening the filing (The Pharma Letter, 18 October 2025). A manufacturing-based rejection sitting on top of a positive pivotal trial is an under-modelled risk in this modality, and per that reporting it has delayed the challenger expected to rival Novartis' Lutathera ^[1].

What happened

Endpoints News reported on 10 August 2026 that the FDA rejected ITM's radiopharmaceutical for neuroendocrine tumors over manufacturing issues, delaying a potential challenger to Novartis' approved Lutathera, and that ITM said the agency cited manufacturing concerns ^[1]. An AuntMinnie headline of the same date designates the action a Complete Response Letter. The Pharma Letter identifies the asset as ITM-11, that is ¹⁷⁷Lu-edotreotide, and Oncology News Central puts the indication at gastroenteropancreatic neuroendocrine tumors. Fierce Pharma frames the rejection as manufacturing rather than efficacy, BioSpace reports the same manufacturing basis, and STAT called the decision a surprise.

Those corroborating items reached Prognyx through a news aggregator, as headlines whose links resolve to the aggregator rather than to the publisher; they are named here and deliberately not cited as links, and none can be quoted beyond its headline. The same holds for the two historical items. Eight of the nine trade items behind this story are in that position, and the Endpoints report ^[1] is the only one Prognyx read on a publisher's own page. The convergence across the trade press is what carries the event; the identity of the asset, the letter's formal designation and the indication rest on that secondary layer alone.

What did not happen is equally load-bearing. No clinical or safety objection is reported in the record reviewed. A phase 3 success was headlined on 28 January 2025, and reinforced at ESMO 2025. A company that clears the efficacy bar and stalls at the manufacturing bar has a different problem, a different timeline, and a different set of fixes than one that missed on hazard ratios.

Why it matters

A decay clock is a manufacturing constraint no other oncology modality carries in the same form — Prognyx's reading, not a sourced claim. The Lancet Oncology's theranostics Series covers radiochemistry and the production of radionuclides alongside its account of the field's recent advances and impending challenges ^[4] — written before this letter, and now with an FDA action sitting next to it.

The strategic reading: in radioligand therapy, the pivotal readout is no longer the gating event. Isotope supply, radiochemistry, fill-finish and release testing decide when a positive trial becomes a product. Every competitive model that treats a successful phase 3 as the last real hurdle before launch is mis-specified for this modality.

Second-order, the delay preserves the approved position ITM's drug was expected to contest ^[1]. Prognyx has no Lutathera label, approval date, indication wording or revenue figure in the sources reviewed, so the size of that reprieve cannot be quantified here — only its direction.

Who is exposed, by name

The competitive set assembled for this briefing is a registry listing. It states what each company is testing, never how well anything works, and none of these records establishes that a trial is registration-directed. Every registry status below is a snapshot: the two lutetium-177 records carry a snapshot date of 15 June 2026, and Prognyx did not establish a retrieval date for the three competitive-landscape records.

Molecular Partners AG is running NCT07278479, a phase 1/2 study of the lead-212 radioconjugate [212Pb]Pb-MP0712 in small cell lung cancer and other DLL3-expressing solid tumors, recruiting ^[5]. Exposure: same modality class, the same isotope-supply and radiochemistry burden, and a neuroendocrine-adjacent population.

Abdera Therapeutics Inc. sponsors NCT06736418, a phase 1 dose-optimisation study of the actinium-225 conjugate 225Ac-ABD147 in small cell lung cancer and large-cell neuroendocrine carcinoma of the lung after platinum-based chemotherapy; the trial is active but no longer recruiting ^[7]. Exposure: an alpha-emitter programme whose isotope supply and radiochemistry will face the same review standard the FDA is reported to have applied to ITM.

DualityBio Inc. sponsors NCT05914116, a phase 1/2a study of DB-1311/BNT324 in advanced or metastatic solid tumors, recruiting ^[6]. The registry listing places it in the neuroendocrine competitive set assembled here; it does not state the asset's modality, and it does not place the trial in gastroenteropancreatic neuroendocrine tumors. Prognyx's reading, not a state of the world this record establishes: any asset positioned against a radiopharmaceutical in this population has more room while the radioligand challenger is held out of the US market.

Adjacent lutetium-177 clinical activity in the registry set: the National Cancer Institute's phase 1 of peposertib added to lutetium Lu 177 dotatate in pancreatic neuroendocrine tumors, active but no longer recruiting (NCT04750954) ^[2], and a Jonsson Comprehensive Cancer Center phase 1 biopsy study of resistance to ¹⁷⁷Lu-PSMA in metastatic castration-resistant prostate cancer, recruiting (NCT05398302) ^[3].

What Prognyx could not verify

One block, stated once. ITM's own release announcing the letter was not among the sources reviewed, so every detail here is journalist-mediated, and all but one of the news items reached Prognyx as aggregator headlines that could not be opened at the publisher — which is why the asset name, the Complete Response Letter designation and the indication are carried here as named trade reporting rather than as settled fact, and why they are not cited as links. The exact wording of the FDA's objection is unknown: a facility inspection finding, the chemistry-manufacturing-and-controls data package, a third-party fill-finish site or isotope supply are all consistent with what was reported, and none is established. Whether the letter also raised any clinical or safety point alongside manufacturing is not established; "manufacturing-only" is an inference from headlines, not a sourced fact. No ClinicalTrials.gov record for the pivotal phase 3 is in the sources reviewed, so its design, comparator, primary endpoint and effect sizes are unverified beyond a headline reporting a phase 3 success. The original filing acceptance date and any target action date are not in the record reviewed, and neither is a resubmission class nor a stated resubmission timeline. The EU status of any marketing authorisation application for this asset is likewise unsourced here.

What to watch

The next informative disclosure is ITM's own — a statement of what the letter demanded, how the company intends to respond, and any date attached to it. Prognyx could not confirm that such a statement exists or is scheduled.

No decision window can be dated from this record. There is no resubmission date, no resubmission class and no published target action date in the sources reviewed, and Prognyx has no sourced figure for the length of the review clock a resubmission would start — so any US decision date now circulating is not supportable from what Prognyx examined.

After that: a ClinicalTrials.gov record for the pivotal phase 3, which would convert a headline into numbers a competitor can benchmark; any inspection-related public record touching ITM's production sites; and refreshed registry status for NCT04750954 and NCT05398302, whose entries here rest on a snapshot from 15 June 2026 ^[2][3].

The now-what

If you run a radioligand programme: stress-test the package across the four axes any manufacturing-based letter can touch — facility inspection readiness, the chemistry-manufacturing-and-controls data package, third-party fill-finish, isotope supply — before your pivotal reads out. The cost of a manufacturing hold is now measured in a competitor's uncontested quarters, and the field has a worked example ^[1][4].

If you compete in neuroendocrine tumors with a non-radioligand asset: the window in which the radioligand challenger reported here is absent from the US market has been extended by an amount nobody can yet quantify. Whether that shifts enrolment dynamics in that population is a hypothesis to test, not a state of the world this record establishes.

If you are on the BD side: an asset with a positive phase 3 and a manufacturing gap of unknown scope is a different valuation object than one with a data problem. The diligence question is narrow and answerable: what exactly did the letter ask for, and does ITM control the site that has to answer it.

Verdict. Threat level to Lutathera: reduced, for an interval nobody has bounded. Threat level to every other radioligand developer: raised, and it stays raised until the field has a worked precedent for clearing this kind of letter. Window to act: from now to ITM's next disclosure, which is not on any public calendar Prognyx could confirm.